News | Molecular Imaging | June 29, 2015

North America Accounts for Highest Share of Global Nuclear Medicine Diagnostic Market

Fusion imaging and wide availability of radiopharmaceuticals expected to push market up nearly $7 billion by 2019

nuclear medicine diagnostic market, North America, PET, SPECT, Mordor

June 29, 2015 - The Global Nuclear Medicine Diagnostics Market report from Mordor Intelligence revealed that North America accounts for the highest share of the global nuclear medicine diagnostic market, followed by Europe and Asia-Pacific. Asian countries are expected to show a growing trend in the diagnostic sector because of increasing diagnostic procedure demand and the rise of the medical device industry.

The market is segmented into two major segments: single photon emission computed tomography (SPECT), which includes technetium-99m (TC-99m), thallium-201 (TL-201), iodine (I-123) and others; and positron emission tomography (PET), including fluorine-18, rubidium-82 (RB-82) and others. By application the market is segmented into SPECT (cardiology, lymphoma, thyroid, neurology and others) and PET (oncology, cardiology, neurology and others). By geography the market is segmented into North America, Europe and Asia-Pacific etc.

The global nuclear medicine diagnostic (PET and SPECT) market is expected to grow from an estimated $ 8.77 billion in 2014 to $15.51 billion in 2019, at an estimated compound annual growth rate (CAGR) of 12.08 percent.

Major factors for the growth of the market are increasing use of SPECT and PET in medical diagnostics, increased awareness about radiopharmaceuticals and ready availability of radiopharmaceuticals. It has novel applications for diseases such as Alzheimer's and a continually expanding oncology segment. However, some of the major constraints for the market are shorter half- life of radioisotopes, high capital investment, regulatory guidelines and reimbursement issues.

Until now, SPECT imaging was the mainstream modality for nuclear medicine applications like nuclear cardiology procedures. However, the trend is soon going to flip upside down because of a global shortage of molybdenum-99 isotope, which in turn will lead to a shortage of technetium-99, the daughter product of molybdenum. Hence, PET imaging products, which includes hybrid PET-CT scanners, holds a potential increase in market size in coming years. The cost associated with PET-CT service contracts is usually 105 percent of the system purchase price annually and can be as high as $275,000 per year.

The emerging market trend is fusion of nuclear imaging with different diagnostic imaging products such as PET/CT, SPECT/CT, and MRI/PET (magnetic resonance imaging). This provides a full gamut of imaging scans through the same unit and at the same time. The PET market is expected to witness more growth compared to SPECT imaging, as it provides higher resolution images, and the lack of availability of technetium-99m is propelling the industry to look for alternative diagnostic procedures.

Analyzing the application segment of SPECT and PET, PET is majorly being used in oncology because of good quality of imaging. SPECT, however, is mostly being used in the cardiology segment, accounting for almost 90 percent of the market share in cardiology. North America has totaled 5,729 PET procedures, while the number of PET procedures in the Asia-Pacific region is 369,636, owing to the increased demand of nuclear medicine diagnostic procedures in developing nations.

Major players in the market include Cardiarc Ltd., Digirad Corp., Gamma Medica Inc., GE Healthcare and Hologic Inc. Mergers and acquisitions of small and medium-sized manufacturers is another strategy being adopted by multinational players to enter in overseas markets.

For more information: www.mordorintelligence.com

Related Content

MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Videos | SPECT-CT | December 12, 2018
This is a walk around of the new Spectrum Dynamics Veriton SPECT-CT nuclear imaging system introduced at the 2018 ...
Spectrum Dynamics Sues GE for Theft, Misappropriation of Trade Secrets and Unfair Competition
News | SPECT Imaging | December 06, 2018
Single-photon emission computed tomography (SPECT) cardiac imaging company Spectrum Dynamics filed a lawsuit Dec. 6,...
Subtle Medical Receives FDA Clearance, CE Mark for SubtlePET
Technology | PET Imaging | December 05, 2018
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtlePET. Subtle...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...